Clinical Trials Logo

Clinical Trial Summary

This study investigates if the administration of terlipressin reduces complications after major liver surgery.


Clinical Trial Description

Background

Surgery offers the only potential cure in many patients with primary or metastatic liver cancer. Extending the limits and improving safety of liver resection would allow more patients to benefit from surgery and to increase their survival. The prerequisite for successful and safe liver surgery is the optimal regeneration of the remaining hepatic tissue in order to fulfill the metabolic demands of the patient. Liver regeneration depends on a correct portal pressure and portal blood flow. In the preliminary results the investigators show an elevation of portal pressure post partial hepatectomy in mice. Pharmacologic reduction of such elevated portal pressure using terlipressin, a vasopressin agonist, was associated with improved liver regeneration.

Objective

Surgery offers the only potential cure in many patients with primary or metastatic liver cancer. Extending the limits and improving safety of liver resection would allow more patients to benefit from surgery and to increase their survival. Liver regeneration depends on a correct portal pressure and portal blood flow. Pharmacologic reduction of elevated portal pressure using terlipressin, a vasopressin agonist, is potentially associated with improved liver regeneration. Aim: To perform a prospective randomized trial comparing terlipressin versus placebo in patients undergoing major hepatic resection.

Methods ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01921985
Study type Interventional
Source University Hospital Inselspital, Berne
Contact
Status Terminated
Phase Phase 2
Start date November 2013
Completion date March 2018

See also
  Status Clinical Trial Phase
Recruiting NCT03791190 - RCA for CRRT in Liver Failure and High Risk Bleeding Patients N/A
Recruiting NCT05989958 - The Safety and Tolerability Study of HepaCure in Chinese Subjects With Acute-On-Chronic Liver Failure Phase 1
Completed NCT02557724 - Mobilization of Mesenchymal Stem Cells During Liver Transplantation
Recruiting NCT01698723 - A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E Virus Phase 2
Completed NCT01425385 - Autoregulation Assessment During Liver Transplantation N/A
Completed NCT01404793 - SPME For Metabolomics And Concomitant Measurements Of Rocuronium Bromide Levels In Liver Transplantation N/A
Completed NCT00808691 - Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit N/A
Completed NCT03864497 - Myocardial Perfusion Imaging in Liver Transplantation Candidates
Completed NCT00287235 - Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS) N/A
Completed NCT03650920 - Hepatitis C Virus (HCV) Positive Liver Grafts in HCV Negative Recipients N/A
Recruiting NCT05517668 - Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose Phase 2
Recruiting NCT05726032 - Empagliflozin in Patients With Cirrhosis and Ascites Phase 2
Recruiting NCT04548596 - NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
Recruiting NCT02331745 - RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure Phase 4
Not yet recruiting NCT01961440 - Prognosis Scoring System for Acute-on-Chronic Liver Failure N/A
Active, not recruiting NCT01221454 - Allogenic Bone Marrow Stem Cell Transplantation in Liver Failure Phase 2
Completed NCT00772148 - Pharmacokinetics of LCP-Tacroâ„¢ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients Phase 2
Completed NCT05592106 - Gd-EOB-DTPA-enhanced T1 Map for Predicting Postoperative Liver Failure
Not yet recruiting NCT06014320 - Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease
Recruiting NCT04221672 - The Effect of Terlipressin on Recovery of Liver Function After Hepatectomy Phase 3